Summary of DURB Recommendations

October 17, 2024

Meeting Date	Action Item	Status/DURB recommendation	Impact/Comments
July 2024	Proposed addendum to the protocol for Dupixent (dupilumab)	- The Board recommended the addendum to the protocol	
	Proposed addendum to the protocol for calcitonin gene-related peptide (CGRP) inhibitors	- The Board recommended the addendum to the protocol	
	Proposed addendum to the protocol for Vyjuvek (beremagene geperpavec)	- The Board recommended the addendum to the protocol	
	Proposed addendum to the protocol for Duchenne Muscular Dystrophy products	- The Board recommended the protocol with suggested changes to: - Criterion #5 to read: Medication is prescribed by or in consultation with a pediatric/adult neurologist, or a specialist who is an expert in the treatment of DMD and other neuromuscular disorders - Same as above for criterion #4 in the continuation of therapy section - Delete criterion #4 in the continuation of therapy section which referred to making patient's weight available	These changes will be made and presented at the next meeting
	Proposed protocol for Qelbree (viloxazine)	- The Board recommended the protocol with suggested change to: a. Delete criterion #3 which required treatment failure with atomoxetine, clonidine, or guanfacine	This change will be made and presented at the next meeting
	Proposed protocol for Wegovy to reduce the risk of major adverse cardiovascular events (MACE	- The Board recommended the protocol	
April 2024	Proposed protocol for Ingrezza® (valbenazine)	- he Board recommended the protocol	
	Proposed protocol for Egrifta® (tesamorelin)	- The Board recommended the protocol with suggested change to delete criterion #4c (waist circumference)	Updated information was presented at the next meeting
	Proposed addendum to the protocol for Spinal Muscular Atrophy (SMA) products	- The Board recommended the addendum to the protocol	
	Proposed addendum to the protocol for Direct Acting Antivirals (for hepatitis C) products	- The Board recommended the protocol suggested change to criterion #B3 to read: Provide previous treatment history including medication, length of therapy, and whether the patient is a relapser, noncompliant, or reinfected	Updated information was presented at the next meeting

Summary of DURB Recommendations

Meeting Date	Action Item	Status/DURB recommendation	Impact/Comments
	Proposed addendum to Zurzuvae (zuranolone) protocol	- The Board recommended the protocol with suggestion to change criterion #3 to read: Medication is prescribed by or in consultation with an appropriate healthcare provider with planned follow up.	Updated information was presented at the next meeting
January 2024	Proposed addendum to the protocol for calcitonin gene-related peptide (CGRP) inhibitor products	- The Board recommended the protocol	
	Proposed addendum to the protocol for proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor products	- The Board recommended the protocol with suggested changes to criterion #3 for initial approval and criterion #4 for subsequent requests.	Updated information was presented at the next meeting
	Proposed update to the protocol for Synagis (palivizumab)	- The Board recommended the protocol	
	Proposed addendum to the protocol for Lumizyme (alglucosidase alfa) for Pompe disease	- The Board recommended the protocol	
	Proposed protocol for Zurzuvae (zuranolone)	- The Board recommended the protocol with suggested changes to criteria #1, 2, 4 for initial approval and criterion #2 in continuation of therapy section	Updated information was presented at the next meeting
October 2023	Proposed addendum to biologic receptor modifiers (BRMs) protocol for plaque psoriasis	- The Board recommended the protocol	
	Proposed protocol for Kanuma (sebelipase alfa)	- The Board recommended the protocol	
	Proposed protocol for Vyjuvek (beremagene geperpavec)	- The Board recommended the protocol with suggested changes to criterion #5	The updated information was presented at the next meeting
	Proposed addendum to Duchenne muscular dystrophy products protocol	- The Board recommended the protocol with suggested changes to criteria # 2, 6 and 10	The updated information was presented at the next meeting